Genmab Logo

Genmab

Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.

GMAB | CO

Overview

Corporate Details

ISIN(s):
DK0010272202 (+2 more)
LEI:
529900MTJPDPE4MHJ122
Country:
Denmark
Address:
Carl Jacobsens Vej 30, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genmab is an international biotechnology company focused on creating and developing differentiated antibody therapeutics for the treatment of cancer and other serious diseases. The company leverages its proprietary antibody science and pioneering technology platforms to innovate next-generation treatments. Genmab's core activities involve the discovery, development, and commercialization of antibody-based products, often in collaboration with strategic partners. Its purpose is to improve the lives of patients by harnessing the power of antibodies to transform medical care.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-19 18:55
Regulatory Filings
English 206.6 KB
2025-11-19 18:55
Director's Dealing
English 7.0 KB
2025-11-18 20:58
Share Issue/Capital Change
English 176.0 KB
2025-11-18 20:58
Share Issue/Capital Change
English 7.8 KB
2025-11-18 17:30
Regulatory Filings
English 244.6 KB
2025-11-18 17:30
Regulatory Filings
English 27.2 KB
2025-10-14 12:23
Earnings Release
English 216.5 KB
2025-10-14 12:23
Earnings Release
English 7.7 KB
2025-09-29 07:08
M&A Activity
English 25.9 KB
2025-09-29 07:08
M&A Activity
English 234.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 175.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 7.2 KB
2025-09-23 15:18
Major Shareholding Notification
English 2.9 MB
2025-09-09 20:57
Director's Dealing
English 7.1 KB
2025-09-09 20:57
Director's Dealing
English 202.5 KB

Automate Your Workflow. Get a real-time feed of all Genmab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genmab

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Genmab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

REGENXBIO Inc. Logo
Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
United States of America
RGNX
Rein Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.
United States of America
RNTX
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel
REKA
Relay Therapeutics, Inc. Logo
Developing precision medicines for oncology & genetic diseases by analyzing protein motion.
United States of America
RLAY
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia
REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden
RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America
REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America
RVPH
Revolution Medicines, Inc. Logo
A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
United States of America
RVMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.